JP2023503840A5 - - Google Patents

Info

Publication number
JP2023503840A5
JP2023503840A5 JP2022527933A JP2022527933A JP2023503840A5 JP 2023503840 A5 JP2023503840 A5 JP 2023503840A5 JP 2022527933 A JP2022527933 A JP 2022527933A JP 2022527933 A JP2022527933 A JP 2022527933A JP 2023503840 A5 JP2023503840 A5 JP 2023503840A5
Authority
JP
Japan
Prior art keywords
variant
decoy
tegfr
subset
variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022527933A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023503840A (ja
JP7819923B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/060505 external-priority patent/WO2021097278A1/en
Publication of JP2023503840A publication Critical patent/JP2023503840A/ja
Publication of JP2023503840A5 publication Critical patent/JP2023503840A5/ja
Application granted granted Critical
Publication of JP7819923B2 publication Critical patent/JP7819923B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022527933A 2019-11-14 2020-11-13 免疫療法のための組成物および方法 Active JP7819923B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962935308P 2019-11-14 2019-11-14
US62/935,308 2019-11-14
PCT/US2020/060505 WO2021097278A1 (en) 2019-11-14 2020-11-13 Compositions and methods for immunotherapy

Publications (3)

Publication Number Publication Date
JP2023503840A JP2023503840A (ja) 2023-02-01
JP2023503840A5 true JP2023503840A5 (cg-RX-API-DMAC7.html) 2023-11-20
JP7819923B2 JP7819923B2 (ja) 2026-02-25

Family

ID=75912441

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022527933A Active JP7819923B2 (ja) 2019-11-14 2020-11-13 免疫療法のための組成物および方法

Country Status (11)

Country Link
US (1) US20220387555A1 (cg-RX-API-DMAC7.html)
EP (1) EP4058035A4 (cg-RX-API-DMAC7.html)
JP (1) JP7819923B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220101151A (cg-RX-API-DMAC7.html)
CN (1) CN115151267B (cg-RX-API-DMAC7.html)
AU (1) AU2020381514A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022009303A2 (cg-RX-API-DMAC7.html)
CA (1) CA3157416A1 (cg-RX-API-DMAC7.html)
IL (1) IL292872A (cg-RX-API-DMAC7.html)
MX (1) MX2022005535A (cg-RX-API-DMAC7.html)
WO (1) WO2021097278A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220387555A1 (en) * 2019-11-14 2022-12-08 Ludwig Institute For Cancer Research Ltd Compositions and methods for immunotherapy
US20240207319A1 (en) * 2021-05-06 2024-06-27 Ludwig Institute For Cancer Research Ltd Compositions and methods for immunotherapy
WO2024261339A1 (en) 2023-06-23 2024-12-26 Tigen Pharma Sa Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations
WO2025133340A1 (en) 2023-12-21 2025-06-26 Ludwig Institute For Cancer Research Ltd Heterodimeric proteins comprising dimerization motifs and methods of using

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US7381405B2 (en) 2002-10-15 2008-06-03 The United States Of America As Represented By The Department Of Health And Human Services Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer
CA2597584A1 (en) * 2005-02-15 2006-08-24 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
IL298125A (en) 2013-02-26 2023-01-01 Memorial Sloan Kettering Cancer Center Preparations and methods for immunotherapy
EP3789487A1 (en) * 2013-04-03 2021-03-10 Memorial Sloan Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
EP3177640B1 (en) * 2014-08-08 2020-05-06 The Board of Trustees of the Leland Stanford Junior University High affinity pd-1 agents and methods of use
EP3217993A1 (en) * 2015-07-20 2017-09-20 Virttu Biologics Limited Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood
SG10201913573UA (en) * 2015-10-01 2020-03-30 Heat Biologics Inc Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
EP3184548A1 (en) 2015-12-23 2017-06-28 Miltenyi Biotec GmbH Chimeric antigen receptor with cytokine receptor activating or blocking domain
CN106967684A (zh) 2016-01-13 2017-07-21 北京马力喏生物科技有限公司 共表达抗EGFRvIII嵌合抗原受体和无功能EGFR受体的转基因淋巴细胞及其用途
CN109715205A (zh) * 2016-08-19 2019-05-03 库瑞瓦格股份公司 用于癌症治疗的rna
GB201620070D0 (en) * 2016-11-28 2017-01-11 Autolus Ltd Signal transduction modifying protein
JP2020509773A (ja) * 2017-03-17 2020-04-02 センティ バイオサイエンシズ インコーポレイテッド 免疫調節性細胞回路
EP3606518A4 (en) 2017-04-01 2021-04-07 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
WO2019070755A1 (en) * 2017-10-02 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
CN108997492B (zh) * 2018-07-19 2022-04-12 海珂分子(北京)科技有限责任公司 高亲和力的pd1胞外区突变体多肽及相关融合蛋白
US20220387555A1 (en) * 2019-11-14 2022-12-08 Ludwig Institute For Cancer Research Ltd Compositions and methods for immunotherapy
US20230414660A1 (en) * 2020-11-13 2023-12-28 Ludwig Institute For Cancer Research Ltd Pd-1 decoy variants for immunotherapy

Similar Documents

Publication Publication Date Title
Castellarin et al. Driving cars to the clinic for solid tumors
Yao et al. Trispecific antibodies for cancer immunotherapy
AU2014225788B2 (en) Engager cells for immunotherapy
Liu et al. Driving better and safer HER2-specific CARs for cancer therapy
US20250043013A1 (en) Nucleic acids encoding il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy
JP2019150066A5 (cg-RX-API-DMAC7.html)
JP2018523485A5 (cg-RX-API-DMAC7.html)
JP2021502810A5 (cg-RX-API-DMAC7.html)
Murad et al. Advances in the use of natural receptor-or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies
JP2019535262A5 (cg-RX-API-DMAC7.html)
WO2023020423A1 (en) Ror1 car or ror1 /cd19 dual car t cells for the treatment of tumors
JP2020516276A5 (cg-RX-API-DMAC7.html)
JP2018529327A5 (cg-RX-API-DMAC7.html)
JP2021512614A5 (cg-RX-API-DMAC7.html)
CN109053899B (zh) 一种含人转铁蛋白抗原表位序列的嵌合体抗原受体
CN110035768A (zh) 嵌合抗原受体
JP7227630B2 (ja) Y182t突然変異を有するt細胞-抗原カプラおよびその方法ならびに使用
RU2018104703A (ru) Опухолеспецифичное антитело против egfr и его применение
US20230130737A1 (en) Multifunctional Heteromultimeric Constructs
JP2023527621A5 (cg-RX-API-DMAC7.html)
JP2022553292A5 (cg-RX-API-DMAC7.html)
JP2022548112A5 (cg-RX-API-DMAC7.html)
CA3109635A1 (en) Cell sorting systems and methods of use
Yu et al. CAR NK cell therapy for solid tumors: potential and challenges
CN114853897B (zh) 抗cd19/cd22/cd3三特异性抗体及用途